Humor and Quirks Humor and Quirks

Exclusive-Germany's Merck KGaA in talks to buy US biotech firm Springworks, sources say


Published on 2025-02-10 12:22:43 - MSN
  Print publication without navigation

  • Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics, according to people familiar with the matter.

Merck KGaA, a German science and technology company, is currently in discussions to acquire SpringWorks Therapeutics, a U.S.-based biotech firm, according to sources familiar with the matter. SpringWorks Therapeutics specializes in developing treatments for severe rare diseases and cancer, with its lead candidate, nirogacestat, recently receiving FDA approval for treating desmoid tumors. The potential acquisition could enhance Merck's portfolio in oncology and rare diseases, aligning with its strategic focus on expanding its healthcare business. However, details such as the deal's value and structure remain undisclosed, and there's no confirmation yet on whether an agreement will be reached.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/general/exclusive-germany-s-merck-kgaa-in-talks-to-buy-us-biotech-firm-springworks-sources-say/ar-AA1yLgI5 ]